Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Q4 2025 Earnings Presentation
37 slides from Corvus Pharmaceuticals's earnings presentation, Mar 12, 2026
Slide 1: Corvus Corporate Presentation
Corvus Corporate Presentation March 2026 The Power to Control Immunity
Slide 2: Forward-Looking Statements / Safe Harbor
Forward-Looking Statements / Safe Harbor This presentation and the accompanying oral presentation contain “forward‐looking” statements related the potential safety and efficacy of the Company’s product candidates; the potential use of soquelitinib to treat a variety of hematological cancers and auto
Slide 3: First-in-Class Immune Modulators with Broad Opportunity in Immune Disease
First-in-Class Immune Modulators with Broad Opportunity in Immune Disease Highly selective ITK inhibition; blocks multiple cytokines and rebalances Novel MOA immune response Oral Administration Oral dosing in markets dominated by injectables Safety/efficacy seen in placebo-controlled Phase 1 AD; ini
Slide 4: Soquelitinib: Opportunity Could Parallel Rituximab & Ibrutinib
Soquelitinib: Opportunity Could Parallel Rituximab & Ibrutinib Target the intersection of immune diseases and lymphoma Rituximab (CD20) Platform Ibrutinib (BTK) Impacts Initial opportunity Developed by key elements clinical value across oncology members of of immune demonstrated and Corvus Team syst
Slide 5: Advancing ITK's Broad Therapeutic Potential
Advancing ITK’s Broad Therapeutic Potential ITK is a crucial target---key is specificity Phase 3 Oncology Immunotherapy Dermatology • PTCL • Atopic dermatitis Phase 1 AD trial demonstrated • Solid tumors Phase 1/2 • Hidradenitis suppurativa positive safety and efficacy results + support novel MOA in
Slide 6: Soquelitinib Blocks Th2 and Th17
Soquelitinib Blocks Th2 and Th17 Modulation of T cell differentiation ITK blockade leads to reduction in Th2, Th17 ITK involved in T cell differentiation and cytokines T H1 Th1 cells play a role in cancer T H1 Th1 cells play a role in cancer T-bet T-bet cell and viral elimination cell and viral elim
Slide 7: ITK Regulates Switch from Th17 to Tregs
ITK Regulates Switch from Th17 to Tregs Rebalancing immunity leads to durable responses ITK involved in T cell differentiation ITK blockade leads to switch to Treg T H1 Th1 cells play a role in cancer T H1 T-bet T-bet cell and viral elimination APC APC Naïve T H2 IL-4 Naïve T H2 IL-4 ITK ITK CD4+ GA
Slide 8: Soquelitinib is Highly Selective for ITK
Soquelitinib is Highly Selective for ITK Kinase Binding Comparison Specificity of Binding Soquelitinib Ibrutinib Drug Discovery 2024, 1:2 8
Slide 9: Soquelitinib Effects Multiple Inflammatory Pathways
Soquelitinib Effects Multiple Inflammatory Pathways Comparison to other agents Th2 Th17 ILC2 Treg IL-4 IL-5 IL-13 IL-31 IL-17 IL-21 IL-22 SOQUELITINIB DUPIXENT® EBGLYSS NEMLUVIO® RINVOQ® SOQUELITINIB Inhibits cells responsible for Restores immune balance production and control of by enhancing T regs
Slide 10: Soquelitinib Broad Opportunities in Multiple Immune Diseases
Soquelitinib Broad Opportunities in Multiple Immune Diseases IL-17 Driven Fibrotic / Other Th2 Driven Diseases IL-5 Driven Diseases Diseases Inflammatory Diseases Asthma Psoriasis Eosinophilic Systemic sclerosis Granulomatosis Atopic dermatitis Psoriatic arthritis Pulmonary fibrosis Polyangiitis Eos
Slide 11: Large and Growing I&I Market w/ Unmet Need for Orals
Large and Growing I&I Market w/ Unmet Need for Orals Only 4% of current $110B market attributed to orals 130 Million I&I Patients1 $170B I&I Market Projected2 30M20M Eligible for Advanced Treatments 60M Significant opportunity for orals3 30M 23M 15M 2.5M1.2M .25M .2M SS HS IPF IBD Psor COPD AD Asthm
Slide 12: Results Show Soquelitinib Could Become a Leading Oral Therapy for Atopic Dermatitis
Results Show Soquelitinib Could Become a Leading Oral Therapy for Atopic Dermatitis Positive Deeper, Active in Biomarkers Clinical Durable Challenging Support ITK Results Responses Patients Novel MOA EASI 75: 75% of patients Cohort 4 showed additional Cohorts 1-4 demonstrate Immune rebalancing: clin
Slide 13: Increasing Efficacy and Deeper Response with Continued Dosing
Increasing Efficacy and Deeper Response with Continued Dosing (8 week dosing vs 4 week dosing) Soquelitinib vs. Placebo Endpoints (EASI 75, EASI 90, IGA 0 or 1) 4 weeks 8 weeks 80 75 70 60 50 % Patients 50 40 33 33 30 25 25 25 25 20 20 17 10 8 8 0 0 0 0 0 0 0 PBO Cohorts 1-3 SQL Cohort 1 (n=12) SQL
Slide 14: Atopic Dermatitis Placebo Control Phase 1 Design
Atopic Dermatitis Placebo Control Phase 1 Design Soquelitinib 100 mg BID Cohort 1 Randomized N = 12 Study Design 3:1 4 weeks N =16 Placebo • Endpoints: treatment N=4 • Primary: safety Soquelitinib 200 mg QD • Secondary: % change in EASI, EASI75, Randomized N = 12 EASI90, IGA 0 or 1 Cohort 2 3:1 • De
Slide 15: Patient Baseline Characteristics
Patient Baseline Characteristics More difficult to treat population with more prior systemic therapies 4-week 8-week Cohorts 1 and 2 Cohort 3 Cohorts 1–3 Cohort 4 Soquelitinib Soquelitinib Soquelitinib 100 mg BID or 200 mg QD 200 mg BID Placebo 200 mg BID Placebo (n=24) (n=12) (n=12) (n=12) (n=12) A
Slide 16: Efficacy Results at 4 Weeks
Efficacy Results at 4 Weeks Cohorts 1-3 Soquelitinib Placebo Cohorts 1 and 2 Cohort 3 Combined (N=24) (N=12) (N=12) Change EASI Mean % 54.6 64.8 34.4 Reduction EASI 50 (%pts) 75 83 58 EASI 75 (%pts) 29 50 0 EASI 90 (%pts) 4 8 0 IGA 0 or 1 (%pts) 21 25 0 16
Slide 17: Mean Percent Reduction in EASI
Mean Percent Reduction in EASI Cohorts 1, 2, and 3 17
Slide 18: Immune Rebalance
Immune Rebalance Durable remission with increase in Tregs in Cohort 3 Treg increase in blood 200 On Treatment Off Treatment PBO Combined % change over baseline 150 SQL Cohort 1 SQL Cohort 2 100 SQL Cohort 3 50 0 -50 D1 D28 D58 • Change from baseline at Day 28 and at Day 58 (n=9 Cohort 1, n=12 Cohort
Slide 19: Disease Rebounds When Treatment is Stopped
Disease Rebounds When Treatment is Stopped Common with JAK inhibitors and others Percentage change in EASI • Abrocitinib (JAKi) doses 10, 30, 100, 200 mg QD for 12 weeks • Disease rebounds when treatment stops JAMA Derm 155:1371, 2019 19
Slide 20: Cohort 3 Demonstrates Clinically Meaningful Reduction in Itch
Cohort 3 Demonstrates Clinically Meaningful Reduction in Itch Improvement in Patient Reported Pruritus (PP-NRS) ≥ 4-point decrease in PP-NRS at Day 28 (Evaluable patients with baseline PP-NRS ≥4) Soquelitinib Placebo Cohort 3 1/11 (9%) 4/10 (40%)* *Of the remaining patients, two had baseline PP-NRS
Slide 21: Efficacy Results at 8 Weeks
Efficacy Results at 8 Weeks Cohort 4 achieved 75% EASI 75 Cohort 4 8-week Soquelitinib Placebo (N=12) (N=12) Change EASI Mean % Reduction 72 40* EASI 50 (%pts) 11 (92) 3 (30)* EASI 75 (%pts) 9 (75) 2 (20)* EASI 90 (%pts) 3 (25) 0 (0) IGA 0 or 1 (%pts) 4 (33) 0 (0) Flare (requiring rescue meds) (%pts
Slide 22: Mean Percent Reduction in EASI Cohort 4
Mean Percent Reduction in EASI Cohort 4 Increased efficacy with longer duration of treatment (8 weeks) 22
Slide 23: Soquelitinib in Patients with Prior Systemic Therapy
Soquelitinib in Patients with Prior Systemic Therapy Prior systemic therapy experience in 35% of patients Soquelitinib Placebo N=48 N=24 Systemic therapies n (%) n (%) Dupilumab 6 (13) 5 (21) JAKi 2 (4) 2 (8) Corticosteroids 5 (10) 5 (21) Investigational Drugs 7 (15) 3 (13) ≥ 2 systemic therapies 6
Slide 24: Efficacy in Patients with Prior Systemic Therapy (Cohorts 1–4)
Efficacy in Patients with Prior Systemic Therapy (Cohorts 1–4) Comparable efficacy in patients with prior systemic therapy All Patients (Cohorts 1–4) Prior Systemic Therapy (Cohorts 1–4) 24
Slide 25: Efficacy in Patients with Prior Systemic Therapy (200 mg dose)
Efficacy in Patients with Prior Systemic Therapy (200 mg dose) Comparable efficacy in patients with prior systemic therapy All Patients (200 mg BID dose) Prior Systemic Therapy (200 mg BID dose) 25
Slide 26: Response in Systemic Treatment Resistant Patients
Response in Systemic Treatment Resistant Patients Cohorts 3 & 4 Study Baseline Age/Gender Prior Treatment Resistant % EASI change Treatment EASI Soquelitinib 60/F Dupixent® 24.6 –91% Soquelitinib 18/M Dupixent®, anti-OX40L 23.8 –96% Dupixent®, Methotrexate, Soquelitinib 52/M 41.5 –27% Rinvoq® Dupixe
Slide 27: Safety Summary
Safety Summary 4-week 8-week Cohorts 1–3 Cohort 4 Soquelitinib Placebo Soquelitinib Placebo (n=36) (n=12) (n=12) (n=12) Subjects with AEs* 15 (41.7%) 4 (33.3%) 5 (41.7%) 6 (50%) Severe (Grade ≥3) AEs 0 0 0 0 Serious AEs 0 0 0 0 AEs leading to study drug 0 0 0 0 discontinuation *All Grade 1-2 AEs not
Slide 28: Adverse Events of Interest
Adverse Events of Interest Soquelitinib Placebo AEs N = 48 N = 24 n (%) n (%) Subjects with AEs 20 (41.7) 10 (41.7) Infections and infestations 4 (8.3) 3 (12.5) COVID-19 1 (2.1) 0 Skin infection 1 (2.1) 2 (8.3) Upper Respiratory 2 (4.2) 1 (4.2) Hepatobiliary disorders 0 0 Renal and urinary disorders
Slide 29: Soquelitinib Reduces Th2 cells and Effects Multiple Pathways
Soquelitinib Reduces Th2 cells and Effects Multiple Pathways Biomarkers consistent with MOA Reduction in Th2 cells Change in IL-17 and Change in serum IL-4 Change in serum IL-5 scRNA seq* Data 1 TARC 0 0.0276 100 (p=0.06) % change from baseline 500 % change from -20 % change from baseline 300 Baseli
Slide 30: Competitive Efficacy Data
Competitive Efficacy Data Placebo-adjusted EASI-75 and IGA 0/1 16 Week Phase 3 Data* Phase 1b Data** JAK1 4 Week 8 Week Inhib ITK ITK Inhib IL-13 64 Inhib IL-4Rα mAb mAb 54 ITK 55 Inhib 50 % Patients 43 36 IL-31 36 mAb 33 28 30 25 22 15 12 IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 N =
Slide 31: Randomized Double Blind Phase 2 Trial
Randomized Double Blind Phase 2 Trial Initiated in Q1 2026 12 Weeks Treatment with Extended 90d Follow-up Eligibility Study Design Endpoints • Moderate to Severe AD • N=200 • Primary: % change in EASI • 1:1:1:1 randomization: from Baseline to W12 • ≥ 18 years of age • Secondary: • Chronic AD for ≥ 1
Slide 32: Atopic Dermatitis: Significant Market Opportunity
Atopic Dermatitis: Significant Market Opportunity Potential First 30M In Class ITKi High Unmet Need Atopic Dermatitis (AD) patients in the G7 Novel MOA and Oral Safe & Effective SystemicTherapies • Up to 50% patients will fail systemic biologic therapy • Black box warnings and monitoring required wi
Slide 33: Randomized Phase 3 Trial in PTCL Enrolling
Randomized Phase 3 Trial in PTCL Enrolling Potential for first fully FDA approved drug for PTCL Eligibility Clinical Trial Endpoints • Relapsed / refractory PTCL 1:1 randomization to • Primary: Progression free survival • PTCL-NOS • Soquelitinib 200 mg po BID • Secondary: • AITL • Standard of care N
Slide 34: Responses In Cutaneous T Cell Lymphoma
Responses In Cutaneous T Cell Lymphoma Similar immune characteristics to atopic dermatitis • 63 y.o. female with CTCL • Extensive plaque and nodular skin Baseline disease, large cell transformation • PR at first disease assessment (9 weeks) • Continued tumor regression at 25+ mo. • Similarities to a
Slide 35: Summary and Plans
Summary and Plans Significant potential in Atopic Dermatitis and beyond Strong Clinical Data in Novel MOA and Multiple Value Atopic Dermatitis Attractive Profile Creation Opportunities Efficacy comparable to leading Immune rebalancing has potential Near-term I&I development biologic and JAKi in a wi
Slide 36: Multiple Soquelitinib Value-Driving Milestones
Multiple Soquelitinib Value-Driving Milestones Cash runway into 2Q28 Atopic dermatitis Cohort 4 data January 2026 Atopic dermatitis Phase 2 trial initiation Q1 2026 Atopic dermatitis Phase 1 data presentation (oral) SID 2026 Hidradenitis suppurativa Phase 2 trial initiation 2026 Asthma Phase 2 trial
Slide 37: Corvus Corporate Presentation
Corvus Corporate Presentation THANK YOU March 2026 The Power to Control Immunity
Corvus Pharmaceuticals — Q4 2025 Earnings Presentation on 6ix